^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    DNMT3A mutation

    i
    Other names: DNMT3A, DNA Methyltransferase 3 Alpha, DNA (Cytosine-5-)-Methyltransferase 3 Alpha, DNA (Cytosine-5)-Methyltransferase 3A, DNA MTase HsaIIIA, DNA Cytosine Methyltransferase 3A2, DNA Methyltransferase HsaIIIA, DNMT3A2, Dnmt3a
    Entrez ID:
    1788
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Apply
    Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (NCT03418038)
    Phase 2
    Mayo Clinic
    Recruiting
    Last update posted :
    04/02/2024
    Initiation :
    03/23/2018
    Primary completion :
    12/01/2025
    Completion :
    03/01/2026
    IDH1 • BCL2 • IDH2 • DNMT3A • SF3B1 • TET2 • SRSF2 • U2AF1 • CD4 • ZRSR2
    |
    IDH2 mutation • DNMT3A mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation
    |
    cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • decitabine • dexamethasone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection
    Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies (NCT01823198)
    Phase 1/2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    11/07/2023
    Initiation :
    06/11/2013
    Primary completion :
    05/10/2022
    Completion :
    05/10/2022
    FLT3 • DNMT3A • TET2
    |
    FLT3 mutation • KIT mutation • DNMT3A mutation • TET2 mutation
    |
    fludarabine IV • Proleukin (aldesleukin) • busulfan
    Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT02960646)
    Phase 1
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    02/16/2023
    Initiation :
    01/18/2017
    Primary completion :
    02/13/2023
    Completion :
    02/13/2023
    FLT3 • DNMT3A • ASXL1 • KMT2A • TET2 • PHF6
    |
    FLT3 mutation • DNMT3A mutation • Chr t(4;14) • Chr t(14;16) • MLL rearrangement
    |
    Rituxan (rituximab) • cyclophosphamide • melphalan • Truxima (rituximab-abbs) • fludarabine IV • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar) • cyclophosphamide intravenous
    Ex Vivo Expanded NK Cells Infusion Decrease Relapse Post Hematopoietic Stem Cell Transplantation (NCT05250362)
    Phase 1/2
    Sichuan University
    Recruiting
    Last update posted :
    03/15/2022
    Initiation :
    03/01/2022
    Primary completion :
    02/28/2025
    Completion :
    12/31/2025
    FLT3 • DNMT3A • TET2
    |
    FLT3 mutation • DNMT3A mutation • Chr del(7q)
    |
    cytarabine • cyclophosphamide
    Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR (NCT02497404)
    Phase 2
    Weill Medical College of Cornell University
    Completed
    Last update posted :
    09/22/2021
    Initiation :
    02/13/2015
    Primary completion :
    06/17/2020
    Completion :
    06/17/2021
    FLT3 • DNMT3A • RUNX1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • ZRSR2
    |
    DNMT3A mutation • ASXL1 mutation • MLL rearrangement • MLL rearrangement • U2AF1 mutation
    |
    azacitidine • Campath (alemtuzumab) • melphalan • fludarabine IV
    Prophylactic Donor Lymphocyte Infusion After Allo-PBSCT for Patients With Very High-risk Hematologic Malignancies (NCT03771222)
    Phase 2
    Chinese PLA General Hospital
    Unknown status
    Last update posted :
    12/13/2018
    Initiation :
    01/01/2019
    Primary completion :
    12/01/2020
    Completion :
    12/01/2021
    TP53 • FLT3 • DNMT3A • TET2
    |
    FLT3-ITD mutation • DNMT3A mutation • TET2 mutation
    |
    decitabine
    QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML (NCT03365661)
    Phase 2
    Masonic Cancer Center, University of Minnesota
    Withdrawn
    Last update posted :
    11/09/2018
    Initiation :
    10/30/2018
    Primary completion :
    01/01/2023
    Completion :
    01/01/2023
    TP53 • FLT3 • KIT • DNMT3A • RUNX1 • ASXL1 • HLA-DRB1 • HLA-B • HLA-C
    |
    TP53 mutation • FLT3-ITD mutation • FLT3 mutation • KIT mutation • DNMT3A mutation • ASXL1 mutation
    |
    Anktiva (nogapendekin alfa inbakicept-pmln)